Latest news with #RNA
Sydney Morning Herald
03-06-2025
- Entertainment
- Sydney Morning Herald
‘Game-changer': Construction finishes on upgraded Exhibition station
People catching the train to the Caravan and Camping Supershow on Wednesday will be the first to experience the much-anticipated revamp of the train station at Brisbane's RNA Showgrounds. The upgrade of the Exhibition station after years of construction brings new lifts, wider platforms, better shading and accessibility features such as hearing aid loops. But the station will operate only for major events, including Brisbane's annual agricultural show, the Ekka, and this week's caravan and camping show, until Cross River Rail opens in 2029. RNA chief executive Brendan Christou said the facilities would be a 'game-changer' for his organisation and the events precinct around Bowen Hills, which was set to host an athletes village for the Olympic and Paralympic Games in 2032. The station was still under construction during last year's Ekka, but would be operational for this year's event, in about 10 weeks. 'It's been a tough couple of years and we've worked really well with Translink in particular and QR on the alternative plans, but there's nothing like coming to the show on a train,' Christou said. 'We look forward to everyone coming and enjoying the experience of this new station. I'm sure they'll see what we see, which is this fantastic, much more accessible, easy to access, station for all of those patrons of the show.' Queensland Transport Minister Brent Mickelberg said the station would be open year-round when Cross River Rail opened to passengers in 2029.
The Age
03-06-2025
- Entertainment
- The Age
‘Game-changer': Construction finishes on upgraded Exhibition station
People catching the train to the Caravan and Camping Supershow on Wednesday will be the first to experience the much-anticipated revamp of the train station at Brisbane's RNA Showgrounds. The upgrade of the Exhibition station after years of construction brings new lifts, wider platforms, better shading and accessibility features such as hearing aid loops. But the station will operate only for major events, including Brisbane's annual agricultural show, the Ekka, and this week's caravan and camping show, until Cross River Rail opens in 2029. RNA chief executive Brendan Christou said the facilities would be a 'game-changer' for his organisation and the events precinct around Bowen Hills, which was set to host an athletes village for the Olympic and Paralympic Games in 2032. The station was still under construction during last year's Ekka, but would be operational for this year's event, in about 10 weeks. 'It's been a tough couple of years and we've worked really well with Translink in particular and QR on the alternative plans, but there's nothing like coming to the show on a train,' Christou said. 'We look forward to everyone coming and enjoying the experience of this new station. I'm sure they'll see what we see, which is this fantastic, much more accessible, easy to access, station for all of those patrons of the show.' Queensland Transport Minister Brent Mickelberg said the station would be open year-round when Cross River Rail opened to passengers in 2029.
Yahoo
30-05-2025
- Business
- Yahoo
Cofactor Genomics Presents Breakthrough Work Combining RNA and AI to bring Precision Medicine to Immunotherapy at RNA Society's 30th Annual Meeting
SAN DIEGO, May 30, 2025--(BUSINESS WIRE)--Cofactor Genomics announced the latest validation results for OncoPrism®, Cofactor's breakthrough RNA-based diagnostic approach at the RNA Society's 30th Annual Meeting. The talk, presented by Dr. Kevin Flanagan (Cofactor's VP of Translational Science), "Bringing Precision Medicine to Cancer Immunotherapy with a Robust RNA Diagnostic Platform", highlighted OncoPrism's dramatic improvement in the prediction of patient responses to cancer immunotherapies relative to other diagnostics. Using an AI approach and RNA expression data from patient tumors, Cofactor's OncoPrism platform has demonstrated a 300–400% improvement in predictive performance compared to other clinical tests. Cofactor also presented for the first time the validation results for OncoPrism-NSCLC, with non-small cell lung cancer (NSCLC) representing the single largest patient population eligible for immune checkpoint inhibitor (ICI) immunotherapy. Validated with patients enrolled across 12 clinical sites, OncoPrism outperformed PD-L1, with higher sensitivity and specificity in NSCLC. Cofactor's approach has already proven its clinical value. OncoPrism-HNSCC and OncoPrism-NSCLC are available for clinical use from Cofactor's CAP-accredited, CLIA-certified laboratory. In addition, OncoPrism-HNSCC has secured Medicare reimbursement approval. The robustness of Cofactor's platform comes from its proprietary Health Expression Models – multidimensional RNA models built with machine learning. These Heath Expression Models decode complex RNA expression patterns to measure the immune status of the tumor microenvironment, delivering high predictive accuracy beyond single-gene tests. This unique approach ensures robust, reproducible results across different patient populations and tumor types. "OncoPrism is bridging the precision medicine gap by providing clinicians with reliable insights that far surpass the predictive power of conventional biomarkers," said Dr. Flanagan. "Leveraging RNA's rich information, we can identify immunotherapy responders with unprecedented accuracy. It's an honor to present these findings at the RNA Society's 30th anniversary meeting, which highlights how RNA science is transforming patient care." Cofactor's presentation at the 30th Annual Meeting of the RNA Society of recent clinical cases where OncoPrism is already changing clinical treatment decisions and improving patient outcomes underscores the growing importance of RNA in precision medicine. Celebrating three decades of RNA research, the conference provides a high-profile forum to share Cofactor's advancements, emphasizing how RNA innovations are driving a new era of personalized cancer immunotherapy. Cofactor's leadership in RNA diagnostics exemplifies how decades of RNA research are now being translated into tangible clinical benefits – improving the selection of therapies like checkpoint inhibitors and ultimately aiming for better patient outcomes in cancer care. About Cofactor: Cofactor Genomics is a commercial stage diagnostics company that bridges the precision medicine gap by decoding RNA to solve the biggest problems in healthcare. It accomplishes this by unlocking RNA's use as a transformational barometer of health through its PRISM database of patented Health Expression Models (HEMs). HEMs are a departure from common and often uninformative gene mutation panel tests. They represent the latest advancements in machine learning and RNA, transforming billions of biological RNA data points into Cofactor's high-dimensional RNA models of biology, disease, and therapy response. Cofactor's pioneering work in RNA modeling has been published in The Journal of ImmunoTherapy of Cancer, The Journal of Molecular Diagnostics, and recognized by Nature Scientific Reports as breakthrough work in cancer. Cofactor is supported and partnered with 38 healthcare systems, representing 20% of US healthcare. Cofactor's OncoPrism is CAP/CLIA-validated and Medicare-approved. Learn more from and LinkedIn. View source version on Contacts Contact: press@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Glasgow Times
26-05-2025
- Entertainment
- Glasgow Times
Glasgow author Breea Keenan wins prestigious award
Breea Keenan scooped the Debut Romantic Novel Award at the Romantic Novelists' Association's (RNA) Romantic Novel of the Year Awards 2025. Published by Headline, an imprint of Hachette UK, Plot Twist impressed judges with its originality and fresh voice in the romantic fiction genre. Read more: 'Emotional rollercoaster': Mum who beat cancer completes challenge in friend's memory Breea, a former journalist with a first-class honours degree in English Literature, Journalism, and Creative Writing from Strathclyde University, now works in marketing and communications. She said: "It was fantastic to attend the Romantic Novelists' Association Awards for the first time this year and meet the amazing authors, publishing representatives, literary agents, and RNA members. "I was absolutely thrilled when Plot Twist was announced as the winner. "It is fantastic to get such positive recognition, especially as a debut author." The prestigious awards ceremony was held at the Leonardo Royal London City Hotel on May 19 and hosted by prize-winning author Brigid Coady. Awards were presented by leading figures in romantic fiction, including RNA President and Sunday Times bestselling author Sue Moorcroft and RNA Chair and award-winning author Seána Talbot. The evening also included the presentation of the Joan Hessayon Award for New Writers, sponsored by the estate of the late Dr David Hessayon, and presented by Maryam Oliver (writing as Melissa Oliver), who won the award in 2020 and now serves as its coordinator. Seána Talbot said: "The RNA is proud to celebrate the work and achievements of these talented authors, whose work represents the extraordinary strength, success, and diversity of romantic fiction as a genre. "Huge congratulations to our worthy winners and many thanks to our respected reader-judges and to the awards volunteers, without whom the awards simply could not happen." RNA winners 2025 (Image: Supplied) Read more: Top five BBQ hacks from Glasgow MasterChef champion Sharon Ibbotson, RNA awards coordinator, said: "I am delighted to congratulate our winners on their well-deserved awards. "Thanks also to our wonderful reader-judges, without whom these awards could not take place.' The RNA Awards, established in 1960, celebrate excellence in romantic fiction across all forms. They are highly respected within the UK publishing industry, with previous winners including bestselling authors Santa Montefiore, Joe Heap, Julie Cohen, and Milly Johnson.
Yahoo
17-05-2025
- Business
- Yahoo
Eli Lilly and Co (LLY): Expands Genetic Hearing Loss Pipeline with $1.3B RNA Therapy Partnership
On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion. Rznomics will lead early-stage research, while Lilly handles clinical development and commercialization using RNA editing, a reversible alternative to CRISPR. A healthcare professional working on a computer terminal with a patient in the background. The collaboration complements Lilly's existing genetic hearing loss pipeline, including AK-OTOF, a Phase I/II AAV gene therapy targeting OTOF gene mutations. Early data showed hearing restoration in a trial participant within 30 days. Eli Lilly and Company (NYSE:LLY) also signed a $1.4 billion deal with Sangamo Therapeutics for CNS gene therapy in April 2025. Industry focus on genetic hearing loss treatments is growing, with Regeneron's DB-OTO showing measurable hearing improvements in 10 of 11 pediatric patients. Rznomics, which raised $58 million in funding, sees the partnership as a step toward global biotech expansion. CEO Seong-Wook Lee emphasized the potential of precision RNA therapeutics in treating previously untreatable diseases. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None.
